The current financial score of Relmada Therapeutics Inc is 5.49, ranking 352 out of 388 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Financials
2.04
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.63
Total revenue
Operating profit
Total assets
SG&A
Relevant data have not been disclosed by the company yet.
Operational Efficiency
4.00
Cash flow from operating activities
Income after tax
Relevant data have not been disclosed by the company yet.
Growth Potential
6.75
Cash flow from operating activities
Total revenue
Relevant data have not been disclosed by the company yet.
Shareholder Returns
7.03
Free cash flow
Relevant data have not been disclosed by the company yet.